Overview
Most patients with metastatic non-small cell lung cancer (NSCLC) have cancer spread to multiple organ sites, and prognosis varies dramatically depending on which organs are involved. Current staging systems don't adequately capture this complexity, making it difficult for doctors to predict outcomes and tailor treatment plans. This study developed a framework based on real-world patterns of metastatic spread.
Using data from over 75,000 patients with metastatic NSCLC in Flatiron Health’s US NSCLC Panoramic Database, inclusive of more than 336,000 patients with NSCLC, researchers identified six distinct patterns of metastasis: bone-dominant, pleural-dominant, liver-dominant, brain-dominant, adrenal-dominant, and high metastatic burden. These patterns showed markedly different survival outcomes—ranging from median overall survival of 7.2 months (high metastatic burden) to 15.7 months (pleural-dominant). Notably, outcomes associated with individual organ sites varied depending on the overall metastatic pattern. Treatment responses also differed by pattern: immunotherapy outperformed targeted treatment in the adrenal-dominant group, while combinations of immunotherapy plus chemotherapy performed better than immunotherapy alone in pleural and liver-dominant disease in terms of median overall survival.
Why this matters
This research reveals that specific patterns of organ metastasis have prognostic significance beyond simply knowing which organs are involved. By identifying distinct "risk phenotypes," clinicians can better counsel patients about expected outcomes and potentially tailor treatment strategies. This framework could ultimately improve outcomes by enabling more personalized treatment selection based on individual metastatic patterns, rather than applying one-size-fits-all approaches.